Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
65 hedge funds and large institutions have $10.8M invested in Elevation Oncology in 2025 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 12 increasing their positions, 24 reducing their positions, and 32 closing their positions.
24% more capital invested
Capital invested by funds: $8.76M → $10.8M (+$2.08M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7.28% less ownership
Funds ownership: 57.16% → 49.88% (-7.3%)
10% less funds holding
Funds holding: 72 → 65 (-7)
22% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 32
50% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$481K |
| 2 |
DAM
Deltec Asset Management
New York
|
+$479K |
| 3 |
Millennium Management
New York
|
+$475K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$314K |
| 5 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$302K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.23M |
| 2 |
BlackRock
New York
|
-$938K |
| 3 |
State Street
Boston,
Massachusetts
|
-$288K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$216K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$179K |
ELEV Hedge Fund Activity: Q2 2025 in Review
65 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q2 2025, worth a combined $10.8M — up 24% from $8.76M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ELEV and 25 opened new positions — a net loss of 7 holders — while 24 trimmed existing stakes and 12 added.
The largest buyer was Opaleye Management, opening a new position worth an estimated $481K. The largest seller was Tang Capital Management, exiting entirely with an estimated $1.23M sold.
- 65 institutional investors held Elevation Oncology (ELEV) as of Q2 2025, down from 72 in Q1 2025.
- Funds reported $10.8M of Elevation Oncology stock for Q2 2025, up 24% quarter-over-quarter.
- 25 funds opened new Elevation Oncology positions in Q2 2025 and 32 closed out, a net change of -7 holders.
- The largest Elevation Oncology buyer in Q2 2025 was Opaleye Management, an estimated $481K added.
- The largest Elevation Oncology seller in Q2 2025 was Tang Capital Management, an estimated $1.23M sold.
Based on aggregated 13F filings for Q2 2025.